{"classes":[{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"KIF5B"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.6","upperLimit":"96.2","value":"82.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"title":"CCDC6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.1","upperLimit":"100","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"title":"NCOA4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"19.4","upperLimit":"99.4","value":"75.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"Oncogenic RET activation has been implicated as a driver in both MTC and differentiated TC (DTC). These rearrangements typically produce chimeric transcripts that encode a fusion protein consisting of the RET kinase domain coupled to a protein with a dimerization domain (e.g., KIF5B, CCDC6, NCOA4). RET genotypes were determined by local testing and/or central analysis of ctDNA. ORR was assessed in participants having specific RET rearrangements. ORR was defined as the percentage of participants with a confirmed CR or PR for at least 2 assessments with at least 28 days apart and no PD in between. CR, PR, and PD were defined per RECIST as outlined in the description for OM 3.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who had RET-fusion positive TC received pralsetinib 400 mg, orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG000","title":"RET-fusion Positive TC"}],"paramType":"NUMBER","populationDescription":"RET-altered measurable disease population included participants in the efficacy population who have measurable (target) disease per RECIST v1.1, at baseline according to BICR and sufficient evidence of a RET alteration. As prespecified in the SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. Number analyzed is the number of participants with the specified mutation.","reportingStatus":"POSTED","timeFrame":"Up to approximately 79.8 months","title":"Phase 1 and Phase 2: ORR in RET-fusion Positive TC Participants With Specific RET Gene Status","type":"SECONDARY","unitOfMeasure":"percentage of participants"}